2019: A Year in Review — AMRI's Contributions to Science

040E93C7-D189-4233-A102-58C0580BE529 publications patents

AMRI Research Publications

The following research articles appeared in peer-reviewed scientific journals that described innovations conceived by AMRI scientists. In most of these cases, these manuscripts were written by AMRI lead authors to communicate independent research, or were co-authored with customers to communicate research in collaboration with AMRI. Below are the bibliographies for these publications, including the abstracts, as they appeared with the original documents. The lead author name(s) are indicated.

1. “Comparison of Neisseria gonorrhoeae minimum inhibitory concentrations obtained using agar dilution versus microbroth dilution methods,” Journal of Journal of Microbiological Methods 2019, 157, 93-99.
Link: https://doi.org/10.1016/j.mimet.2019.01.001
Rachael K. Jacobson, Marysa J. Notaro and Grant J. Carr
Lead Discovery, AMRI Buffalo

2. “Practical enantioselective synthesis of (3S,4R)-3-hydroxypiperidine-4-carboxylic acid,” Tetrahedron Letters 2019, 60(20), 1357-1358.
Link: https://doi.org/10.1016/j.tetlet.2019.04.023
Nathan J. Line
AMRI Indianapolis
(3S,4R)-3-hydroxypiperidine-4-carboxylic acid

3. “Mogroside Via1, new isomer of Mogroside VI isolated from Luo Han Guo,” IOSR Journal of Applied Chemistry 2019, 12(5), 1-7.
Link: http://iosrjournals.org/iosr-jac/papers/vol12-issue5/Series-1/A1205010107.pdf
Romila Charan,1 Krishna P. Devkota,1 Mayank Bhanti,2 Naresh C. Vadla,sup>2 Gil Ma,3 Alexandra Walsh,3 George Harrigan3 and Indra Prakash3,*
1Analytical Development, AMRI Albany
2Analytical Development, AMRI Hyderabad
3The Coca-Cola Company, Atlanta, Georgia, USA

4. “Design and synthesis of selective Phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders,” Journal of Medicinal Chemistry 2019, 62(10), 4884-4901.
Link: http://doi.org/10.1021/acs.jmedchem.9b00193
Mark E. Gurney*,1 Richard A. Nugent,1 Xuesheng Mo,1 Janice A. Sindac,1 Timothy J. Hagen,2 David Fox, III,3 James M. O’Donnell,4 Chong Zhang,4 Ying Xu,4 Han-Ting Zhang,5 Vincent E. Groppi,6 Marc Bailie,7 Ronald E. White,8 Donna L. Romero,9 A. Samuel Vellekoop,10 Joel R. Walker,10 Matthew D. Surman,10 Lei Zhu10 and Robert F. Campbell10
1Tetra Discovery Partners, Inc., Grand Rapids, Michigan, USA
2Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois, USA
3Beryllium Discovery Corp., Bainbridge Island, Washington, USA
4Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA
5Departments of Behavioral Medicine & Psychiatry and Physiology, Pharmacology & Neuroscience, Rockefeller Neurosciences Institute, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA
6Michigan Drug Discovery, Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA
7INDS Inc., Ann Arbor, Michigan, USA
8White Global Pharma Consultants, South Cranbury, New Jersey, USA
9Pharma-Vation Consulting, LLC, Chesterfield, Missouri, USA 10Medicinal Chemistry and CADD Departments, AMRI Albany

Phosphodiesterase 4D (PDE4D)

5. “The PO13 crystal structure of ROY,” CrystEngComm 2019, 21, 1363-1368.
Link: https://doi.org/10.1039/C8CE01930D
Karen S. Gushurst,1 Jonas Nyman2,3 and Stephan X. M. Boerrigter*,1
1AMRI West Lafayette
2Small Molecule Design & Development, Eli Lilly and Company, Indianapolis, Indiana, USA
3School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA

PO13 crystal structure

6. “Design, synthesis, and preclinical efficacy of novel nonretinoid antagonists of Retinol-Binding Protein 4 in the mouse model of hepatic steatosis,” Journal of Medicinal Chemistry 2019, 62(11), 5470-5500.
Link: http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b01234
Christopher L. Cioffi,*,1 Boglarka Racz,2 Andras Varadi,2 Emily E. Freeman,3 Michael P. Conlon,3 Ping Chen,3 Lei Zhu,4 Douglas B. Kitchen,4 Keith D. Barnes,3 William H. Martin,5 Paul G. Pearson,6 Graham Johnson,7 William S. Blaner8 and Konstantin Petrukhin*,2
1Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA
2Department of Ophthalmology, Columbia University Medical Center, New York, New York, USA Departments of
3Medicinal Chemistry and
4Computer Assisted Drug Discovery, AMRI Albany
5WHM Consulting LLC, Lyme, Connecticut, USA
6Pearson Pharma Partners, Westlake Village, California, USA
7NuPharmAdvise LLC, Sanbornton, New Hampshire, USA
8Department of Medicine, Columbia University Medical Center, New York, New York, USA

Retinol-Binding Protein 4

7. “Five new ent-atisene glycosides from Stevia rebaudiana,” Natural Product Communications 2019, 14(7), 1-9.
Link: https://journals.sagepub.com/doi/pdf/10.1177/1934578X19862651
Krishna P. Devkota,1 Romila D. Charan,1 Christopher Priedemann,1 Ryan Donovan,1 Tara M. Snyder,1 Catherine Ramirez,1 George Harrigan,2 Gil Ma*,2 and Indra Prakash2
1Analytical Development, AMRI Albany
2The Coca-Cola Company, Atlanta, Georgia, USA

8. “Synthesis and pharmacological characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3- (hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human Dopamine D1 receptor,” Journal of Medicinal Chemistry 2019, 62(19), 8711-8732.
Link: https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00352
Junliang Hao,*,1 James P. Beck,1 John M. Schaus,1 Joseph H. Krushinski,1 Qi Chen,1 Christopher D. Beadle,1 Paloma Vidal,1 Matthew R. Reinhard,1 Bruce A. Dressman,1 Steven M. Massey,1 Serge L. Boulet,1 Michael P. Cohen,1 Brian M. Watson,1 David Tupper,1 Kevin M. Gardinier,1 Jason Myers,1 Anette M. Johansson,1 Jeffery Richardson,1 Daniel S. Richards,6 Erik J. Hembre,1 David M. Remick,2 David A. Coates,2 Rajni M. Bhardwaj,2 Benjamin A. Diseroad,2 David Bender,2 Greg Stephenson,2 Craig D. Wolfangel,2 Nuria Diaz,2 Brian G. Getman,3 Xu-shan Wang,3 Beverly A. Heinz,3 Jeff W. Cramer,4 Xin Zhou,4 Deanna L. Maren,5 Julie F. Falcone,5 Rebecca A. Wright,5 Stephen N. Mitchell,5 Guy Carter,5 Charles R. Yang,5 Robert F. Bruns1 and Kjell A. Svensson5
1Discovery Chemistry Research and Technologies
2Small Molecule Drug Developmen
3Quantitative Biology
4Drug Disposition
5Neuroscience Discovery, Lilly Research Laboratories, Eli Lilly & Co, Indianapolis, Indiana, USA
6AMRI UK Ltd, Erl Wood Manor, United Kingdom

LY3154207(3) Highly potent, subtype selective D1 PAM No bell-shaped does response curve No tachyphylaxis / 3HBA co-crystal with improved solubility as the developable crystalline form

9. “Structural and functional contributions of lipids to the stability and activity of the photosynthetic cytochrome b6f lipoprotein complex,” Journal of Biological Chemistry 2019, 294, 17758-17767.
Link: https://www.jbc.org/content/294/47/17758
Satarupa Bhaduri,1 Huamin Zhang,2 Satchal Erramilli3 and William A. Cramer*,1
1Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA
2AMRI West Lafayette
3Department of Biochemistry and Molecular Biophysics, University of Chicago, Chicago, Illinois, USA

10. “Discovery of small-molecule antibiotics against a unique tRNA-mediated rRegulation of transcription in gram-positive bacteria,” ChemMedChem 2019, 14(7), 758-769.
Link: https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201800744
Kyla M. Frohlich,1 Spencer F. Weintraub,1 Janeen T. Bell,1 Gabrielle C. Todd,1 Ville Y. P. Väre,1 Ryan Schneider,2 Zachary A. Kloos,1,3 Ebot S. Tabe,3 William A. Cantara,1 Caren J. Stark,1 Urenna J. Onwuanaibe,1 Bryan C. Duffy,4 Maria Basanta-Sanchez,1 Douglas B. Kitchen,4 Kathleen A. McDonough2 and Paul F. Agris*,1

AMRI Research Presented (Oral Papers and Posters)

AMRI scientists also delivered the following presentation during 2019, as a talk given at scientific meeting.

  1. “Development of gamma-secretase modulators for the treatment of Alzheimer’s Disease,” 14th Annual Drug Discovery Chemistry Conference, San Diego, California, April 9, 2019.
    R. Jason Herr
    Medicinal Chemistry Department, AMRI Albany

AMRI Patents

  1. Andres, P.; Diaz, K. M.; Smolenskaya, V. N. Solid forms of a toll-like receptor modulator. U.S. Patent 10,508,117, December 17, 2019.
  2. Matsuo, Y.; Hisada, S.; Nakamura, Y.; Chakrabarti, A.; Rawat, M.; (Rai, S.; Satyanarayana, A. V.; Duan, Z.; Talukdar, A.; Ravula, S.; Decornez, H. Bicyclic compound and use thereof for inhibiting SUV39H2. U.S. Patent 10,508,109, December 17, 2019.
  3. Wagner, S. L.; Mobley, W. C.; Tanzi, R. E.; Johnson, G.; Buckle, R.; Mayhew, N.; Herr; R. J.; Rynearson, K. D. Potent gamma-secretase modulators. U.S. Patent 10,472,346, November 12, 2019.
  4. Han, Y.; Tummanapalli, S.; Siliphaivanh, P.; Spencer, K. Aryl sulfonamides as BLT1 antagonists. U.S. Patent 10,450,309, October 22, 2019.
  5. Reichenbacher, K.; Duguid, R. J.; Ware, J. A.; Phillipson, D. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3- fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate. U.S. Patent 10,442,829, October 15, 2019.
  6. Lippa, B. S.; Wu, X.; Li, Q.; Wrona, I.; Jackson, A. J.; Chenard, B. L.; Liu, C. M.; Liang, G.; Baevsky, M. F.; Earl,R. A.; Mcqueen, L.; Smit, J.; Cowans, B. A. Inhibiting the transient receptor potential A1 ion channel. U.S. Patent 10,428,072, October 1, 2019.
  7. Petrukhin, K.; Cioffi, C.; Johnson, G.; Dobri, N.; Freeman, E.; Chen, P.; Conlon, M.; Zhu, L. Octahydrocyclopentapyrroles, their preparation and use. U.S. Patent 10,421,720, September 24, 2019.
  8. Petrukhin, K.; Cioffi, C.; Johnson, G.; Allikmets, R.; Freeman, E.; Chen, P.; Conlon, M.; Zhu, L. Substituted 4-phenylpiperidines, their preparation and use. U.S. Patent 10,407,433, September 10, 2019.
  9. Han, Y.; Tummanapalli, S.; Siliphaivanh, P.; Spencer, K. Aryl acylsulfonamides as BLT1 antagonists. U.S. Patent 10,370,368, August 6, 2019.
  10. Gurney, M. E.; Hagen, T. J.; Mo, X.; Vellekoop, A. S.; Romero, D. L.; Campbell, R. F.; Walker, J. R.; Zhu, L. Heteroaryl inhibitors of PDE4. U.S. Patent 10,364,258, July 30, 2019.
  11. Quinn, J. F.; Duffy, B. C.; Liu, S.; Wang, R.; Jiang, M. X.; Martin, G. S.; Wagner, G. S.; Young, P. R. Bicyclic bromodomain inhibitors. U.S. Patent 10,363,257, July 30, 2019.
  12. Han, Y.; Lim, J.; Tummanapalli, S.; Siliphaivanh, P.; Spencer, K. Aryl acylsulfonamides as BLT1 antagonists. U.S. Patent 10,336,733, July 2, 2019.
  13. Petrukhin, K.; Cioffi, C.; Johnson, G.; Dobri, N.; Freeman, E.; Chen, P.; Conlon, M.; Zhu, L. 4-phenylpiperidines, their preparation and use. U.S. Patent 10,273,243, April 30, 2019.
  14. Tweedie, S.; Venkatraman, S.; Zeller, J. Continuous flow carboxylation reaction. U.S. Patent 10,273,212, April 30, 2019.
  15. Speerschneider, A. C.; Yamashita, D. S.; Pitis, P. M.; Hawkins, M. J.; Liu, G.; Miskowski Daubert, T. A.; Yuan, C. C. K.; Borbo Kargbo, R.; Herr, R. J.; Romero, D.; Pacofsky, G. J. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same. U.S. Patent 10,246,436, April 2, 2019.
  16. Kharenko, O.; Young, P. R.; Brown, S. D.; Duffy, B. C.; Liu, S. Guzzo, P. Inhibitors of bromodomains. U.S. Patent 10,231,953, March 19, 2019.
  17. Liu, S.; Quinn, J. F.; Duffy, B. C.; Wang, R.; Jiang, M. X.; Martin, G. S.; Zhao, H.; Ellis, M.; Wagner, G. S.; Young, P. R. Substituted bicyclic compounds as bromodomain inhibitors. U.S. Patent 10,226,451, March 12, 2019.
  18. Zeller, J. R.; Venkatraman, S.; Brot, E. C. A.; Iyer, S.; Hall, M. LFA-1 inhibitor and methods of preparation and polymorph thereof. U.S. Patent 10,214,517, February 26, 2019.
  19. Scott, I. L.; Kuksa, V. A.; Gall, A.; Orme, M. W.; Gage, J.; Little, Jr., T. L.; Jiang, Q.; Rossiter, L. M.; McGee, Jr., K. F.; Kubota, R. Styrenyl derivative compounds for treating ophthalmic diseases and disorders. U.S. Patent 10,201,545, February 12, 2019.
  20. Nonnenmacher, M,; Busch, T. Process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters.U.S. Patent 10,196,406, February 5, 2019.
  21. Jiang, M. X.; Molino, B. F.; Liu, S.; Wang, R.; Duffy, B. C.; Quinn, J. F.; Wagner, G. S. Substituted pyridines as bromodomain inhibitors. U.S. Patent 10,179,125, January 15, 2019.
  22. Liu, S.; Quinn, J. F.; Duffy, B. C.; Wang, R.; Jiang, M. X.; Martin, G.S.; Zhao, H.; Ellis, M.; Wagner, G. S.; Young, P. R. Substituted bicyclic compounds as bromodomain inhibitors. U.S. Patent 10,166,215, January 1, 2019.

Compiled by R. Jason Herr, Ph.D. and Wendy Quinn, AMRI

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us